Clinical Trial Update: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia (CLL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Ulm | Conditions: Leukemia, Lymphocytic, Chronic | Phase 2 | Status: COMPLETED